GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

MXCT · Sep 30, 2023

MAXCYTE, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001558370-23-018314General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

17.31% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-198.02% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

301.25% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

173.33% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-335.38% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

150.57% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

86.74% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesHistory building

Jun 30, 20230/7 normalizedLevel 3 Sep 30, 20230/7 normalizedLevel 3 Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/8 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20257/8 normalizedLevel 3 Sep 30, 20257/8 normalizedLevel 3 Dec 31, 20257/8 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3 Jun 30, 20268/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 9.02%
Current: 17.31%
Delta: 8.29%

Cash Generation Decreased

Previous: -179.74%
Current: -198.02%
Delta: -18.28%

Inventory Pressure Increased

Previous: 196.02%
Current: 301.25%
Delta: 105.23%

Margin Increased

Previous: 136.37%
Current: 173.33%
Delta: 36.96%

Profitability Decreased

Previous: -232.54%
Current: -335.38%
Delta: -102.84%

R And D Intensity Increased

Previous: 100.75%
Current: 150.57%
Delta: 49.82%

Sbc Intensity Increased

Previous: 62.59%
Current: 86.74%
Delta: 24.15%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · MXCT Fundamental State →Has State · MAXCYTE, INC. →Transitioned To · MXCT Fundamental State →Transitioned To · MXCT CAPEX_INTENSITY_INCREASED →Transitioned To · MXCT CASH_GENERATION_DECREASED →Transitioned To · MXCT INVENTORY_PRESSURE_INCREASED →Transitioned To · MXCT MARGIN_INCREASED →Transitioned To · MXCT PROFITABILITY_DECREASED →Transitioned To · MXCT R_AND_D_INTENSITY_INCREASED →Transitioned To · MXCT SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.